BC Week In Review | May 19, 2017
Clinical News

SIR-Spheres miss Phase III OS endpoint

Sirtex Medical Ltd. (ASX:SRX) said SIR-Spheres missed the primary endpoint of improving median overall survival (OS) compared to Nexavar sorafenib in the Phase III SARAH trial to treat locally advanced or inoperable hepatocellular carcinoma (HCC)...
BC Week In Review | Jun 20, 2016
Clinical News

SIR-Spheres: Completed Phase III enrollment

Sirtex said investigators completed enrollment of >=360 patients in the open-label, international Phase III SIRveNIB trial comparing a single dose of SIR-Spheres yttrium-90 microspheres vs. twice-daily oral Nexavar sorafenib. SIR-Spheres is approved to treat unresectable...
BC Week In Review | Jun 22, 2015
Clinical News

SIR-Spheres: Additional Phase III data

The trial enrolled patients with non-resectable mCRC that had spread to the liver alone or to the liver plus a limited number of sites outside the liver, including lymph nodes and the lungs. Patients in...
BioCentury | Apr 6, 2015
Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
BC Week In Review | Mar 23, 2015
Clinical News

SIR-Spheres: Preliminary Phase III data

Preliminary data from the open-label, international Phase III SIRFLOX trial in about 518 patients with non-resectable metastatic colorectal cancer (mCRC) showed that first-line treatment with FOLFOX chemotherapy plus a single injection of SIR-Spheres into the...
BC Extra | Mar 18, 2015
Clinical News

Sirtex falls on Phase III SIR-Sphere results

Sirtex Medical Ltd. (ASX:SRX) plummeted A$21.47 (55%) to A$17.53 on Tuesday after SIR-Spheres missed the primary endpoint of significantly improving progression-free survival (PFS) when added to first-line chemotherapy in the Phase III SIRFLOX trial to...
BC Week In Review | Oct 6, 2014
Clinical News

SIR-Spheres regulatory update

Sirtex said European Society for Medical Oncology clinical guidelines recommend the use of radioembolization, specifically with Sirtex's SIR-Spheres, to "prolong time to liver tumour progression" in patients with metastatic colorectal cancer (mCRC) who have failed...
BC Week In Review | Mar 31, 2014
Company News

Guerbet, Sirtex Medical deal

The companies partnered to develop Sirtex's SIR-Spheres microspheres and Guerbet's Lipiodol ethiodized oil to be used in combination or in sequence to treat inoperable primary and secondary liver cancers. The first project under the deal...
BC Week In Review | Oct 7, 2013
Clinical News

SIR-Spheres regulatory update

NHS England will cover the use of selective internal radiation therapy (SIRT) as the first treatment under the new Commissioning through Evaluation (CtE) initiative. CtE allows treatments or services that are not routinely funded by...
BC Extra | Oct 2, 2013
Company News

NHS makes SIRT first treatment available under new initiative

NHS England will cover the use of selective internal radiation therapy (SIRT) as the first treatment under the new Commissioning through Evaluation (CtE) initiative. CtE allows treatments or services that are not routinely funded by...
Items per page:
1 - 10 of 25